Cano Health, Inc. CANOQ
0.24
0.00
0.00%
as of 28 Jun
- Market cap
- $6.6M
- P/E
- 0.0×
Follow CANOQ
Growth Flags
show if company had growth for consecutive years
| Mar '24 | Dec '23 | Sep '23 | Jun '23 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.00 | 0.00 | 0.03 | 0.13 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(0.02) | (0.32) | (1.98) | (24.65) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 1.62 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
(0.04) | (0.01) | 0.34 | 0.45 | |
EV/EBITDA |
0.28 | 0.07 | 0.00 | 0.00 | |
EV/Operating CF |
0.84 | 0.19 | (7.12) | (12.20) | |
EV/FCF |
0.76 | 0.16 | (5.96) | (8.91) | |
Quick Ratio |
0.88 | 0.12 | 0.35 | 0.40 | |
Current Ratio |
0.96 | 0.13 | 0.40 | 0.49 | |
Net Debt/EBITDA |
1.88 | 0.66 | (11.59) | (4.38) | |
Debt/Assets |
0.56% | 5.45% | 83.16% | 57.26% | |
Debt/Equity |
(0.01) | (0.10) | (3.89) | 4.15 | |
Asset Turnover |
1.98 | 2.13 | 1.82 | 1.55 | |
Operating CF/Net income |
0.12 | 0.27 | 0.15 | 0.11 | |
Capex/Depreciation |
(0.04) | (0.01) | (0.02) | (0.22) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
13.02% | 12.02% | 10.26% | 12.97% | |
Intangible Assets out of Total Assets |
0.65 | 0.68 | 0.68 | 0.72 | |
Share Based Compensation of Revenue |
0.58% | 0.12% | (0.52%) | 0.26% | |
Graham Net Nets |
(1,780.11) | (94.83) | (16.86) | (3.42) | |
Graham Number |
1,286.72 | 1,059.04 | 666.23 | 0.00 | |
Earnings Yield |
(152,302.32%) | (4,906.41%) | (778.19%) | (105.76%) | |
Free Cash Flow Yield |
(16,159.84%) | (1,029.45%) | (223.08%) | (39.16%) | |
Revenue per Share |
148.94 | 259.99 | 277.95 | 279.18 | |
Operating CF per Share |
(10.63) | (16.12) | (14.01) | (5.64) | |
Capex per Share |
(0.18) | (0.40) | (2.42) | (2.25) | |
Free Cash Flow per Share |
(10.80) | (16.51) | (16.43) | (7.89) | |
Cash per Share |
39.04 | 34.10 | 14.58 | 10.09 | |
Shareholders Equity per Share |
(219.61) | (194.26) | (91.38) | 85.85 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(219.61) | (194.26) | (91.38) | 85.85 | |
Free Cash Flow |
(49.64) | (45.48) | (46.58) | (21.67) | |
Working Capital |
(11.92) | (1,232.60) | (221.21) | (170.60) | |
Capital Expenditures |
(0.81) | (1.09) | (6.87) | (6.19) | |
Net Current Asset Value |
(1,799.67) | (1,365.92) | (1,326.31) | (1,305.21) | |
EV/EBIT |
0.12 | 0.02 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.01 | |
Net Profit Margin |
(60.74%) | (23.05%) | (33.05%) | (18.36%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
148.22 | 154.81 | 144.77 | 154.08 | |
Average Payables |
87.67 | 107.04 | 123.12 | 97.12 | |
Average Assets |
1,494.96 | 1,471.33 | 1,704.04 | 1,924.36 | |
Average Common Equity |
(252.40) | (20.36) | 261.97 | 538.39 |
Columns are period end dates